BR112022016580A2 - Composições e métodos para induzir uma resposta imune - Google Patents

Composições e métodos para induzir uma resposta imune

Info

Publication number
BR112022016580A2
BR112022016580A2 BR112022016580A BR112022016580A BR112022016580A2 BR 112022016580 A2 BR112022016580 A2 BR 112022016580A2 BR 112022016580 A BR112022016580 A BR 112022016580A BR 112022016580 A BR112022016580 A BR 112022016580A BR 112022016580 A2 BR112022016580 A2 BR 112022016580A2
Authority
BR
Brazil
Prior art keywords
methods
inducing
compositions
immune response
viral vector
Prior art date
Application number
BR112022016580A
Other languages
English (en)
Inventor
C Gilbert Sarah
Lambe Teresa
Sebastian Sarah
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003670.3A external-priority patent/GB202003670D0/en
Priority claimed from GBGB2006608.0A external-priority patent/GB202006608D0/en
Priority claimed from GBGB2007062.9A external-priority patent/GB202007062D0/en
Priority claimed from GBGB2009239.1A external-priority patent/GB202009239D0/en
Priority claimed from GBGB2010569.8A external-priority patent/GB202010569D0/en
Priority claimed from GBGB2016922.3A external-priority patent/GB202016922D0/en
Priority claimed from GBGB2017284.7A external-priority patent/GB202017284D0/en
Priority claimed from GBGB2017677.2A external-priority patent/GB202017677D0/en
Priority claimed from GBGB2018410.7A external-priority patent/GB202018410D0/en
Priority claimed from GBGB2018718.3A external-priority patent/GB202018718D0/en
Priority claimed from GBGB2100034.4A external-priority patent/GB202100034D0/en
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of BR112022016580A2 publication Critical patent/BR112022016580A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA INDUZIR UMA RESPOSTA IMUNE. A invenção refere-se a uma composição que compreende um vetor viral, sendo que o vetor viral compreende ácido nucleico que tem uma sequência polinucleotídica que codifica a proteína spike do coronavírus SARS-CoV2, caracterizada pelo fato de que o dito vetor viral é um vetor à base de adenovírus. A invenção também se refere a usos de tal composição e métodos de tratamento.
BR112022016580A 2020-03-13 2021-03-11 Composições e métodos para induzir uma resposta imune BR112022016580A2 (pt)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GBGB2003670.3A GB202003670D0 (en) 2020-03-13 2020-03-13 Compositions and methods for inducing an immune response
GBGB2006608.0A GB202006608D0 (en) 2020-05-05 2020-05-05 Compositions and methods for inducing an immune response
GBGB2007062.9A GB202007062D0 (en) 2020-05-13 2020-05-13 Compositions and methods for inducing an immune response
GBGB2009239.1A GB202009239D0 (en) 2020-06-17 2020-06-17 Compositions and methods for inducing an immune response
GBGB2010569.8A GB202010569D0 (en) 2020-07-09 2020-07-09 Compositions and methods for inducing an immune response
GBGB2016922.3A GB202016922D0 (en) 2020-10-26 2020-10-26 Compositions and methods for inducing an immune response
GBGB2017284.7A GB202017284D0 (en) 2020-10-30 2020-10-30 Compositions and methods for inducing an immune response
GBGB2017677.2A GB202017677D0 (en) 2020-11-09 2020-11-09 Compositions and methods for inducing an immune response
GBGB2018410.7A GB202018410D0 (en) 2020-11-23 2020-11-23 Compositions and Methods for Inducing an Immune Response
GBGB2018718.3A GB202018718D0 (en) 2020-11-27 2020-11-27 Compositions and methods for inducing an immune response
GBGB2100034.4A GB202100034D0 (en) 2021-01-04 2021-01-04 Compositions and methods for inducing an immune response
PCT/GB2021/050602 WO2021181100A1 (en) 2020-03-13 2021-03-11 Compositions and methods for inducing an immune response

Publications (1)

Publication Number Publication Date
BR112022016580A2 true BR112022016580A2 (pt) 2022-11-16

Family

ID=75108658

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016580A BR112022016580A2 (pt) 2020-03-13 2021-03-11 Composições e métodos para induzir uma resposta imune

Country Status (19)

Country Link
US (1) US20230285532A1 (pt)
EP (1) EP4117723A1 (pt)
JP (1) JP2023517286A (pt)
KR (1) KR20220152248A (pt)
CN (1) CN115720522A (pt)
AU (1) AU2021235248A1 (pt)
BR (1) BR112022016580A2 (pt)
CA (1) CA3171939A1 (pt)
CL (1) CL2022002420A1 (pt)
CO (1) CO2022011811A2 (pt)
CR (1) CR20220501A (pt)
DO (1) DOP2022000184A (pt)
EC (1) ECSP22076973A (pt)
IL (1) IL295630A (pt)
MX (1) MX2022011394A (pt)
PE (1) PE20221758A1 (pt)
TW (1) TW202200198A (pt)
UY (1) UY39131A (pt)
WO (1) WO2021181100A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202307565D0 (en) 2020-04-22 2023-07-05 BioNTech SE Coronavirus vaccine
WO2023026182A1 (en) * 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023135439A1 (en) * 2022-01-17 2023-07-20 Institut Pasteur Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine
GB202201768D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Peptides
GB202201765D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Methods
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
GB201708444D0 (en) * 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Compositions and methods for inducing an immune response

Also Published As

Publication number Publication date
MX2022011394A (es) 2022-10-13
CN115720522A (zh) 2023-02-28
PE20221758A1 (es) 2022-11-11
JP2023517286A (ja) 2023-04-25
TW202200198A (zh) 2022-01-01
CO2022011811A2 (es) 2022-08-30
UY39131A (es) 2021-09-30
CA3171939A1 (en) 2021-09-16
DOP2022000184A (es) 2022-10-16
AU2021235248A1 (en) 2022-09-01
EP4117723A1 (en) 2023-01-18
US20230285532A1 (en) 2023-09-14
KR20220152248A (ko) 2022-11-15
ECSP22076973A (es) 2022-12-30
CL2022002420A1 (es) 2023-04-28
CR20220501A (es) 2023-01-23
IL295630A (en) 2022-10-01
WO2021181100A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
BR112022016580A2 (pt) Composições e métodos para induzir uma resposta imune
BR112018003486A2 (pt) ?molécula, rna, métodos para obter rna, métodos para obter um peptídeo e usos do rna?
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
MX2022002938A (es) Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta).
BR112018001572A2 (pt) método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
BR112019024813A2 (pt) adenovírus recombinantes portando transgenes
BR112018013820A2 (pt) análogos de egf(a) com substituintes de ácido graxo
BR112017013742A2 (pt) politioéter de cura dupla
BR112018070852A2 (pt) composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas
BR112018015696A2 (pt) composições e métodos para gerar uma resposta imune para um flavivírus
BR112017017178A2 (pt) moduladores específicos de alelo de rodopsina de p23h
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
BR112017028205A2 (pt) molécula de rna, vetor, célula hospedeira, composição farmacêutica, kit, e, uso de uma ou mais utrs.
BR112017025339A2 (pt) composições nutricionais contendo um nível elevado de inositol e usos das mesmas
BR112018010639A2 (pt) método de transfecção transitória para produção retroviral.
BR112017004202A2 (pt) composições para intensificar respostas imunes e seus usos
ECSP19090449A (es) Composiciones y métodos para incrementar la vida útil del banano
BR112023018437A2 (pt) Compostos antivirais
BR112018012952A2 (pt) composições para higiene pessoal
BR112018005271A2 (pt) meios para o tratamento de hiv
BR112018068890A2 (pt) dna polimerases marinhas
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
BR112017020643A2 (pt) vacina baseada no vírus da caxumba jeryl lynn 2 recombinante
BR112022004032A2 (pt) Composições probióticas mixotróficas e usos das mesmas no tratamento de distensão abdominal
BR112021019979A2 (pt) Tratamento envolvendo interleucina-2 (il2) e interferon (ifn)